April 2
Azura Ophthalmics to Present New Data Supporting the Potential of AZR-MD-001 to be the First Ophthalmic Keratolytic for Ocular Surface Diseases
Read moreBrandon BioCatalyst is the largest life science investment fund in Australia and New Zealand. We are a unique collaboration between major Australian superannuation funds, CSL, the Australian and New Zealand governments, Australian state governments and more than 50 leading medical research institutes and research hospitals.
Learn more about who we areVaxxas' proprietary Nanopatch™ technology is a needle-free vaccine delivery solution
View ProjectDeveloping a new class of therapeutics that enhance the function of beneficial proteins
View ProjectTargeting long non-coding RNAs for next generation cancer therapies
View ProjectDeveloping the next generation of CAR-T cell therapies to treat solid cancers
View ProjectThe University of Queensland's Australian Institute for Bioengineering and Nanotechnology (AIBN) is an integrated multi-disciplinary research institute bringing together the skills of world-class researchers in the areas of bioengineering and nanotechnology.
ViewThe Walter and Eliza Hall Institute is the oldest medical research institute in Australia and will celebrate its centenary in 2015.
The institute is affiliated with The University of Melbourne and The Royal Melbourne Hospital and offers postgraduate training as the Department of Medical Biology of The University of Melbourne.
QIMR Berghofer is one of Australia’s most successful medical research institutes. The Institute was established 70 years ago by the Queensland Government and has a rich history of scientific discoveries and translational medical research.
ViewBrandon BioCatalyst is innovation in action: We provide a path for taking medical science from conception into the real world.
Our Venture capital model is unique. We don’t simply provide investment, we partner with entrepreneurs to create businesses, run companies and everything necessary to ensure our investments succeed.
Learn moreAzura Ophthalmics to Present New Data Supporting the Potential of AZR-MD-001 to be the First Ophthalmic Keratolytic for Ocular Surface Diseases
Read more$3 million in Funding to Support Early-Stage Biomedtech Projects Focused on Minimising Antimicrobial Resistance Thanks to the CSIRO
Read moreBrandon BioCatalyst, in partnership with ANDHealth, selected by Federal Government to deliver $50m Dementia and Cognitive Decline Incubator
Read moreAravax closes Series B round with US$42m to accelerate Phase 2 development for peanut allergy therapy
Read more